These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8717605)

  • 1. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex.
    Gabriel SM; Davidson M; Haroutunian V; Powchik P; Bierer LM; Purohit DP; Perl DP; Davis KL
    Biol Psychiatry; 1996 Jan; 39(2):82-91. PubMed ID: 8717605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex.
    Hirsch SR; de Belleroche J
    Biol Psychiatry; 1996 Jan; 39(2):79-81. PubMed ID: 8717604
    [No Abstract]   [Full Text] [Related]  

  • 3. [Neuropeptides in Alzheimer's disease].
    Jiménez-Corral C; Morán-Sánchez JC; Alonso-Navarro H
    Rev Neurol; 2006 Mar 16-31; 42(6):354-9. PubMed ID: 16575772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptides in neurological disease.
    Beal MF; Martin JB
    Ann Neurol; 1986 Nov; 20(5):547-65. PubMed ID: 2947536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cortical abnormalities in Alzheimer's disease.
    Foster NL; Chase TN; Mansi L; Brooks R; Fedio P; Patronas NJ; Di Chiro G
    Ann Neurol; 1984 Dec; 16(6):649-54. PubMed ID: 6335378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropeptides in Alzheimer's disease.
    Beal MF; Kowall NW; Mazurek MF
    J Neural Transm Suppl; 1987; 24():163-74. PubMed ID: 2445913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropeptides in Alzheimer's disease, depression and schizophrenia. A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex.
    Perry RH; Dockray GJ; Dimaline R; Perry EK; Blessed G; Tomlinson BE
    J Neurol Sci; 1981 Sep; 51(3):465-72. PubMed ID: 6268760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease.
    Beal MF; Mazurek MF; Svendsen CN; Bird ED; Martin JB
    Ann Neurol; 1986 Oct; 20(4):489-95. PubMed ID: 3789664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease.
    Kowall NW; Beal MF
    Ann Neurol; 1988 Feb; 23(2):105-14. PubMed ID: 2897822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of activation of the plasma kallikrein-kinin system in frontal and temporal cortex in Alzheimer's disease and vascular dementia.
    Ashby EL; Love S; Kehoe PG
    Neurobiol Aging; 2012 Jul; 33(7):1345-55. PubMed ID: 21074291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex.
    Gabriel SM; Bierer LM; Harotunian V; Purohit DP; Perl DP; Davis KL
    Neurosci Lett; 1993 May; 155(1):116-20. PubMed ID: 8103205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuromodulators and Alzheimer's disease].
    Vallet PG; Bouras C
    Encephale; 1988; 14(5):345-51. PubMed ID: 2463900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Somatostatin, cortistatin, and their receptors, as well as dopamine receptors, but not of neprilysin, are reduced in the temporal lobe of Alzheimer's disease patients.
    Gahete MD; Rubio A; Durán-Prado M; Avila J; Luque RM; Castaño JP
    J Alzheimers Dis; 2010; 20(2):465-75. PubMed ID: 20164562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered NCAM expression associated with the cholinergic system in Alzheimer's disease.
    Aisa B; Gil-Bea FJ; Solas M; García-Alloza M; Chen CP; Lai MK; Francis PT; Ramírez MJ
    J Alzheimers Dis; 2010; 20(2):659-68. PubMed ID: 20164549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively correlated with the severity of dementia.
    Heffernan JM; Eastwood SL; Nagy Z; Sanders MW; McDonald B; Harrison PJ
    Exp Neurol; 1998 Apr; 150(2):235-9. PubMed ID: 9527892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotransmitter changes in Alzheimer's disease: implications to diagnostics and therapy.
    Reinikainen KJ; Soininen H; Riekkinen PJ
    J Neurosci Res; 1990 Dec; 27(4):576-86. PubMed ID: 1981917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of neuropeptide systems in schizophrenia: human studies.
    Cáceda R; Kinkead B; Nemeroff CB
    Int Rev Neurobiol; 2007; 78():327-76. PubMed ID: 17349866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease.
    De Souza EB; Whitehouse PJ; Kuhar MJ; Price DL; Vale WW
    Nature; 1986 Feb 13-19; 319(6054):593-5. PubMed ID: 3003585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The comparison of the regional cerebral metabolism rate of glucose in Alzheimer's disease with mild cognitive impairment].
    Cao Q; Jiang K; Liu Y; Zhang M; Xiao S; Zuo C; Huang H
    Zhonghua Yi Xue Za Zhi; 2002 Dec; 82(23):1613-6. PubMed ID: 12667368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single photon emission computerised tomography in elderly patients with Alzheimer's disease and multi-infarct dementia. Regional uptake of technetium-labelled HMPAO related to clinical measurements.
    McKeith IG; Bartholomew PH; Irvine EM; Cook J; Adams R; Simpson AE
    Br J Psychiatry; 1993 Nov; 163():597-603. PubMed ID: 8298827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.